Azienda Ospedaliero-Universitaria di Modena

Running trials

• Not yet recruiting

  Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

  NCT07441408· Phase 3· Bristol-Myers Squibb· Source

• Not yet recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

  NCT07900633· Phase 3· Eli Lilly and Company· Source

• Not yet recruiting

  A Phase 2 trial of AGMB-447 in participants with idiopathic pulmonary fibrosis

  2026-526404-71-00· Phase 2· Agomab Spain S.L.U.· Source

• Not yet recruiting

  A research study to evaluate how well etavopivat works in children with sickle cell disease

  2025-524464-38-00· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  2024-518365-10-00· Phase 3· F. Hoffmann-La Roche AG· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

  NCT07541170· Phase 3· Hoffmann-La Roche· Source

• Not yet recruiting

  Phase 3 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC 6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

  2025-524969-24-00· Phase 3· Revolution Medicines Inc.· Source

• Not yet recruiting

  Sequence Strategy of Immuneoncology (IO-IO) vs IO-tyrosine kinase inhibitors (TKI) followed by TKI in metastatic renal cell carcinoma (mRCC): A randomized phase 3 study Meet uro and FICOG trial. COMBO-Seq trial.

  2025-523903-31-00· Phase 3· Fondazione IRCCS Istituto Nazionale Dei Tumori· Source

• Recruiting

  A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL) - ARIEL-ENGIC 04 EU trial

  2025-521209-42-00· Phase 4· Fondazione GONO G.I.· Source

• Recruiting

  A Phase IIb Study to Evaluate AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

  2025-525016-41-00· Phase 2· AstraZeneca AB· Source

• Not yet recruiting

  triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE

  NCT07440381· Phase 3· Heart Care Foundation· Source

• Not yet recruiting

  Semaglutide for the treatment of visceral obesity in people with HIV with body mass index <30 kg/m2 and without diabetes: a randomized clinical trial to explore immune metabolism, systemic and vascular inflammation assessed with Positron Emission Tomography

  2026-526738-18-00· Phase 2· Azienda Ospedaliero Universitaria Di Modena· Source

• Not yet recruiting

  SNIPER-LTFU: Long-term follow-up study of patients administered with RR001 in the interventional Parent SNIPER study

  2026-525714-59-00· Phase 1/2· Eir Biotherapies S.r.l.· Source

• Recruiting

  A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladder.

  2025-524488-18-00· Phase 2· Astellas Pharma Global Development Inc.· Source

• Recruiting

  A clinical trial to learn about the long-term safety of FUB523 (zigakibart) in people with immunoglobulin A (IgA) nephropathy who have completed previous zigakibart trials

  2024-519638-22-00· Phase 3· Novartis Pharma AG· Source

• Recruiting

  Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens

  2025-524336-19-00· Phase 3· Gilead Sciences Inc.· Source

• Recruiting

  A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer

  NCT07673887· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)

  NCT07656415· Phase 3· Agios Pharmaceuticals, Inc.· Source

• Recruiting

  An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

  NCT07665437· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis

  NCT07516951· Phase 2· Chiesi Farmaceutici S.p.A.· Source

• Recruiting

  A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

  NCT07662213· Phase 3· AstraZeneca· Source

• Recruiting

  Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)

  NCT07284602· Phase 3· PureTech· Source

• Recruiting

  A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

  NCT07554339· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.

  NCT07333066· Phase 3· Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD· Source

• Recruiting

  Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS (PREVAiLS)

  2025-524002-16-00· Phase 3· Ferrer Internacional S.A.· Source

• Not yet recruiting

  Maintenance AVElumab after SECond line platinum-based chemotherapy for metastatic urothelial carcinoma: AVESEC trial – GOIRC-02-2025

  2025-524077-16-00· Phase 2· G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica· Source

• Recruiting

  A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

  NCT07481630· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable

  NCT07430956· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

  NCT07355218· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Recruiting

  ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"

  NCT07381764· Phase 2· Gruppo Oncologico Italia Meridionale· Source

• Recruiting

  AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF

  NCT07194382· Phase 2· Avalyn Pharma Inc.· Source

• Not yet recruiting

  Tailored antiplatelet secondary prevention in non-cardioembolic ischemic stroke: a phase IV gender-stratified randomized controlled trial (TAILOR trial)

  2025-523065-16-00· Phase 4· Azienda Unita Sanitaria Locale Di Bologna· Source

• Recruiting

  A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  NCT07318558· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

  NCT07224360· Phase 2· CSL Behring· Source

• Recruiting

  Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

  NCT07322003· Phase 3· Prilenia· Source

• Not yet recruiting

  XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients

  NCT07381777· Phase 2· Gruppo Oncologico Italiano di Ricerca Clinica· Source

• Recruiting

  Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis

  NCT07230288· Phase 2· AbbVie· Source

• Recruiting

  Phase II randomized trial of XELOX plus DoSTARlimab versus XELOX alone as Consolidation Treatment after Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients – IMMUNOSTAR Trial  -  GOIRC-02-2024

  2024-519798-20-00· Phase 2· G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica· Source

• Recruiting

  Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

  NCT07325292· Phase 3· Sanofi· Source

• Recruiting

  Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

  NCT07284459· Phase 2· Contineum Therapeutics· Source

• Recruiting

  Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.

  NCT07330245· AstraZeneca· Source

• Recruiting

  Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.

  2024-512503-39-00· Phase 4· Medizinische Hochschule Hannover· Source

• Recruiting

  Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia

  2025-520982-39-00· Phase 3· Universita Degli Studi Di Milano Bicocca· Source

• Not yet recruiting

  THE EFFECT OF ROPINIROLE ON FUNCTIONAL CONNECTIVITY AND METACOGNITION IN HEALTHY SUBJECTS

  2025-520800-81-00· Phase 2/3· Universita' Degli Studi Di Modena E Reggio Emilia· Source

• Recruiting

  Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

  NCT07211958· Phase 3· Syndax Pharmaceuticals· Source

• Recruiting

  Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  2025-520555-89-00· Phase 3· Amgen Inc.· Source

• Active, not recruiting

  A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07170150· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Clinical Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation

  NCT07267949· Phase 2· Acesion Pharma· Source

• Recruiting

  A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)

  NCT07194850· Phase 2/3· argenx· Source

Showing 50 of 209.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer15 recruiting
• Childhood cancers9 recruiting
• Colorectal cancer9 recruiting
• Metastatic breast cancer9 recruiting
• Idiopathic pulmonary fibrosis8 recruiting
• Prostate cancer6 recruiting
• Acute myeloid leukaemia5 recruiting
• ALS (motor neurone disease)4 recruiting
• Chronic lymphocytic leukaemia4 recruiting
• Kidney cancer4 recruiting
• Lupus (SLE)4 recruiting
• Melanoma4 recruiting
• Sickle cell disease4 recruiting
• Bladder cancer3 recruiting
• Fatty liver disease (MASLD/MASH)3 recruiting
• Gastric and oesophageal cancer3 recruiting
• IgA nephropathy3 recruiting
• Myelodysplastic syndromes3 recruiting
• Ovarian cancer3 recruiting
• Pancreatic cancer3 recruiting
• Stroke3 recruiting
• Alzheimer disease2 recruiting
• Atrial fibrillation2 recruiting
• Follicular lymphoma2 recruiting
• Head and neck cancer2 recruiting
• HIV2 recruiting
• Obesity2 recruiting
• Primary biliary cholangitis2 recruiting
• Sarcoma2 recruiting
• Systemic sclerosis (scleroderma)2 recruiting
• Type 2 diabetes2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Asthma1 recruiting
• Bronchiectasis1 recruiting
• Cervical cancer1 recruiting
• Charcot-Marie-Tooth disease1 recruiting
• Chronic kidney disease1 recruiting
• Chronic myeloid leukaemia1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Coronary artery disease1 recruiting
• Cystic fibrosis1 recruiting
• Cytomegalovirus infection1 recruiting
• Endometrial cancer1 recruiting
• Epilepsy1 recruiting
• Hidradenitis suppurativa1 recruiting
• High blood pressure1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Liver and biliary tract cancer1 recruiting
• Mesothelioma1 recruiting
• Multiple sclerosis1 recruiting
• Neuroblastoma1 recruiting
• Osteoarthritis1 recruiting
• Parkinson disease1 recruiting
• Psoriasis1 recruiting
• Thalassaemia1 recruiting
• Triple-negative breast cancer1 recruiting
• Tuberculosis1 recruiting

Closed trials

• Completed

  GSK4527226 Open-label Extension Study in Patients with Early Alzheimer's Disease.

  2025-521107-42-00· Phase 2· Glaxosmithkline Research & Development Limited· Source

• Completed

  A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis.

  2023-507705-34-00· Phase 3· Alvotech Swiss AG· Source

• Recruiting

  A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

  NCT07005154· Phase 2· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

  NCT06699849· Phase 2· CSL Behring· Source

• Completed

  A trial to learn how well benralizumab works and how safe it is when given in addition to standard asthma treatments in people with eosinophilic asthma

  2024-515162-13-00· Phase 3· AstraZeneca AB· Source

• Completed

  Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® in combination with Yervoy®

  NCT06587451· Phase 3· H e x a l AG· Source

• Recruiting

  A Randomized, Double-Blind, Placebo-Controlled, MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy

  2023-507097-41-01· Phase 3· Shanghai Junshi Biosciences Co. Ltd.· Source

• Completed

  Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHINE

  NCT06425159· Phase 2/3· Biohaven Therapeutics Ltd.· Source

• Completed

  Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants with Moderate to Severe Atopic Dermatitis.

  NCT06447506· Phase 2· Glaxosmithkline Research & Development Limited· Source

• Completed

  A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe hidradenitis suppurativa

  2024-511360-87-00· Phase 3· MoonLake Immunotherapeutics AG· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa

  NCT06603077· Phase 2· Avalo Therapeutics, Inc.· Source

• Completed

  A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease

  NCT06522997· Phase 2· Bayer· Source

• Completed

  A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)

  2023-506185-31-00· Phase 2/3· Pliant Therapeutics Inc.· Source

• Completed

  A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

  NCT06383403· Phase 3· Ipsen· Source

• Completed

  A study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1

  NCT05870748· Phase 2· Sutro Biopharma Inc.· Source

• Terminated

  A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab

  NCT06241573· Phase 2/3· Boehringer Ingelheim· Source

• Completed

  EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE

  NCT06079190· Phase 2· Glaxosmithkline Research & Development Limited· Source

• Recruiting

  Platform Clinical Study for Conquering Scleroderma

  NCT06195072· Phase 2· Scleroderma Research Foundation, Inc.· Source

• Completed

  A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GSK1070806 SC injection in Adult Participants with Moderate to Severe Atopic Dermatitis

  NCT05999799· Phase 2· Glaxosmithkline Research & Development Limited· Source

• Completed

  A Trial to Investigate TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 β/γ, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)

  2023-506092-10-00· Phase 2· Ascendis Pharma Oncology Division A/S· Source

• Completed

  A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in Adult Participants Ineligible for Intensive Chemotherapy With de Novo Acute Myeloid Leukemia (AML) in Italy

  NCT06058741· AbbVie· Source

• Completed

  A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

  NCT06280391· Phase 2· Sanofi· Source

• Completed

  PH2a, VH3739937 Proof-Of-Concept in TN HIV-1 Infected Adults

  2023-505780-37-00· Phase 2· Viiv Healthcare UK Limited· Source

• Active, not recruiting

  MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06132256· Phase 2· Syndax Pharmaceuticals· Source

• Completed

  Randomised, double-blind, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with MCI or mild dementia due to Alzheimer’s disease (AD)

  2022-503148-41-00· Phase 2· Prinnovation GmbH· Source

• Completed

  A Study to Investigate MBS2320 Patients with IPF

  2023-504418-30-00· Phase 2· Modern Biosciences Limited· Source

• Terminated

  A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382

  NCT06032546· Phase 2· AbbVie· Source

• Completed

  Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine

  NCT05748483· Phase 3· AbbVie· Source

• Completed

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

  NCT06040086· Phase 3· AstraZeneca· Source

• Completed

  Clinical trial of MK-7648A in adults and children with skin cancer

  NCT05665595· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease

  NCT05843578· Phase 2· Agomab Spain S.L.U.· Source

• Completed

  A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF

  NCT05911360· Phase 3· ViiV Healthcare· Source

• Completed

  Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

  NCT05819398· Phase 2/3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effects of PTC857 in Adult Subjects With Amyotrophic Lateral Sclerosis (CARDINALS)

  NCT05349721· Phase 2· PTC Therapeutics Inc.· Source

• Completed

  Phase 2b Study of GSK4532990 in Adults With NASH

  NCT05583344· Phase 2· GlaxoSmithKline· Source

• Completed

  Extension Study Evaluating The Safety And Tolerability of AMX0035

  NCT05619783· Phase 3· Amylyx Pharmaceuticals Inc.· Source

• Completed

  Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION)

  2023-508528-36-00· Phase 3· Merck Healthcare KGaA· Source

• Completed

  A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

  NCT05559580· Phase 2· Boehringer Ingelheim· Source

• Completed

  Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)

  NCT05630807· Phase 3· GlaxoSmithKline· Source

• Completed

  A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT05601882· Phase 3· AbbVie· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Bayer AG· Source

• Completed

  Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications

  NCT05518123· Phase 4· Pfizer· Source

• Completed

  Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use

  NCT05509400· Phase 4· Pfizer· Source

• Completed

  Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

  NCT05255991· Phase 3· United Therapeutics· Source

• Completed

  A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease

  NCT05291234· Phase 2· AbbVie· Source

• Completed

  Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight

  NCT04306315· Phase 4· LEO Pharma· Source

• Completed

  A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache

  NCT05452239· Phase 4· H. Lundbeck A/S· Source

• Active, not recruiting

  A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

  NCT05081609· Phase 1/2· Ascendis Pharma Oncology Division A/S· Source

• Completed

  A study to investigate the safety and efficacy of AMX0035 in patients with Amyotrophic Lateral Sclerosis

  NCT05021536· Phase 3· Amylyx Pharmaceuticals Inc.· Source

Showing 50 of 79.

Conditions

Diseases this institution publishes on or runs trials for.

• Atrial fibrillation52 works · 4 trials
• Migraine23 works · 4 trials
• ALS (motor neurone disease)15 works · 9 trials
• Systemic sclerosis (scleroderma)11 works · 6 trials
• Primary biliary cholangitis5 works · 6 trials
• Cushing's syndrome4 works · 0 trials
• Turner syndrome3 works · 0 trials